ISSN-E: 18735347-02779536

The Role of Folic Acid and Iron Supplementation in the Management of Anemia in Patients with Chronic Kidney Disease

By:
Ayman Mushawweh Awad Alenazi
Aymualenazi@moh.gov.sa
Nursing Specialist
king khaled hospital management of health centers-tabuk
Mariam Ameed albalawi
Nursing technician
ALhamra PHC-tabuk
Maam@moh.gov.sa
Fowz Saad AWad Alhawiti
Nursing technician
ALhamra PHC-tabuk
foalhawiti@moh.gov.sa
Amal Saeed Ghaeb Alghamdi
Nursing Specialist
amalsalghamdi1988@gmail.com
king fahad specials hospital - tabuk training centers
ALHARBI, ABDULLAH FALAH A
Specialist-Nursing
abotmaim2022@gmail.com
mustashfaa eaqlat alsuqur
Bader Falah Ayad Alharbi
Nursing technician
bfalharby@moh.gov.sa
Nawal Sayer Thawab Alharbi
Nursing technician
nowala@moh.gov.sa
hanan Saleh jaroain albalawi
Nursing technician
ALhamra PHC - tabuk
hnansa@moh.gov.sa
Abdullah saeed alghamdi
Nursing specialist
Abdallahgh39@gmail.com
Hajar Jumah Alhawiti
Specialist Nurse
Alhamra primary health care
Hajarj@moh.gov.sa
Saud Eid Alemmrani
Health administration specialist
Mazinup66@gmail.com
Ekram saeed alghamdi
Pediatric specialist
Com111902@gmail.com

ISSN-E: 18735347-02779536

ISSN-E: 18735347-02779536

ABSTRACT

A prevalent symptom among people with chronic kidney disease (CKD) is anemia, which can lower quality of life and raise the risk of cardiovascular disease. This research looks at the effects of iron and folic acid supplements on anemia in patients with chronic renal illness. Our research emphasizes the significance of supplementation in treating iron and erythropoietin deficiencies, the principal causes of anemia in chronic renal disease, as folic acid is critical for erythropoiesis and general blood health. The study compares various iron and folic acid treatment strategies and shows that the combination therapy significantly improves hemoglobin levels and patient outcomes.

Keywords: erythropoiesis, chronic kidney disease, anemia, iron supplementation, folic acid, and patient outcomes.

إن أحد الأعراض الشائعة بين الأشخاص المصابين بأمراض الكلى المزمنة هو فقر الدم، والذي يمكن أن يقلل من جودة الحياة ويزيد من خطر الإصابة بأمراض القلب والأوعية الدموية. يتناول هذا البحث آثار مكملات الحديد وحمض الفوليك على فقر الدم لدى المرضى الذين يعانون من أمراض الكلى المزمنة. ويؤكد بحثنا على أهمية المكملات في علاج نقص الحديد والإريثروبويتين، الأسباب الرئيسية لفقر الدم في أمراض الكلى المزمنة، حيث أن حمض الفوليك ضروري لتكوين كريات الدم الحمراء وصحة الدم العامة. تقارن الدراسة بين استراتيجيات مختلفة لعلاج الحديد وحمض الفوليك وتبين أن العلاج المركب يحسن بشكل كبير مستويات الهيموجلوبين ونتائج المرضى.

الكلمات المفتاحية: تكون كريات الدم الحمراء، مرض الكلى المزمن، فقر الدم، مكملات الحديد، حمض الفوليك، ونتائج المرضى.

ISSN-E: 18735347-02779536

1. INTRODUCTION

Chronic kidney disease (CKD) is a degenerative illness that slowly reduces kidney function and can cause anemia among its many other symptoms. The clinical definition of anemia is a decrease in hemoglobin levels; for men, this is less than 130 g/L and for women, it is less than 120 g/L. Anemia is more common in people with advanced chronic kidney disease (CKD) because the severity of renal impairment increases the frequency of the condition. Anemia in chronic renal illness has a complicated pathophysiology that includes many variables, such as iron shortage, decreased erythropoietin production, and the influence of concomitant conditions. Folic acid stimulates critical metabolic processes, such as nucleotide synthesis, which are necessary for the production of red blood cells. Hemoglobin, the protein in red blood cells that carries oxygen, also relies on iron. Patients with chronic renal illness must take iron supplements because anemia might worsen if iron levels are low. This study examines treatment patterns and their effects on patient outcomes to evaluate the effectiveness of folic acid and iron supplements in controlling anemia in chronic renal disease (Fadrowski et al., 2008).

2. Epidemiology of Anemia in CKD

The past ten years have seen a significant increase in the incidence and prevalence of renal disease both globally and in the US. Between 1988 and 1994, almost 20 million Americans, or 11% of all US adults, had chronic kidney disease (CKD) (stages 1–5), and the incidence and prevalence of renal disease are rising. The terminology of chronic kidney disease (CKD) has changed as the number of cases has increased in recent years (Warady et al., 2015). The National Kidney Foundation (NKF) recommended glomerular filtration rate (GFR) as the primary diagnostic test and chronic kidney disease (CKD) as the preferable label in a consensus statement released in 2001 (Staples et al., 2009). The term chronic kidney disease (CKD) encompasses the full range of renal disease progression, from renal abnormalities with normal GFR (stage 1) to mild CKD. Stage 2: GFR 60-90 ml/min/1.73 m²; Stage 3: GFR 30-60 mL/min/1.73 m²; and Stage 5: Dialysis or kidney transplantation due to severe decline (GFR < 15 mL / m * in / 1.73 * m^2. The administrative term "end-stage renal disease" designates a patient receiving dialysis or a kidney transplant. CKD in nursing home residents has hitherto only been considered to affect individuals in stages 4 and 5. Actually, the majority of CKD patients have no symptoms. The presence of proteinuria or hematuria, for instance, is necessary to alert the physician to stage 1 CKD, which is usually undetectable. From an epidemiological perspective, one of the most significant findings of the past few years has been the identification of the vast majority of individuals with GFRs between 30 and 59 mL/min/1.73 m², which places them at stage 3 CKD. In the US, they comprise the majority of patients who experience the majority of the negative effects of CKD. In the United States, the majority of CKD patients (7.6 million) are in stage 3, with around 400,000 having stage 4 (severe) CKD and over 300,000 receiving dialysis (Kovesdy & Kalantar-Zadeh, 2013). (Figure 1)

Figure 1. The identification of the huge number of individuals with GFRs between 30 and 59 mL/min/1.73 m³.

Both domestically and abroad, renal illness has been steadily on the rise over the past decade. The incidence and prevalence of renal sickness are on the rise, and between 1988 and 1994, over 20 million Americans, or 11% of all US adults, were affected by chronic kidney disease (CKD) (stages 1-4). The term chronic kidney disease (CKD) has changed due to the rise in its prevalence in recent years. In 2001, the National Kidney Foundation (NKF) released a statement that indicated glomerular filtration rate (GFR) as the primary diagnostic instrument and chronic kidney disease (CKD) as the recommended term (Atkinson et al., 2010). We include all stages of renal disease progression in chronic kidney disease (CKD). Stage 1 is renal

abnormalities with normal GFR. Stage 2 is moderate CKD. Depending on the stage, the glomerulonephritis reversal (GFR) can range from 60 to 90 ml/min/1.73 m² in Stage 2, 30 to 60 mL/min/1.73 m² in Stage 3, and end-stage renal disease (GFR < 15 mL/m * in / 1.73 * m^2) in Stage 5, which requires dialysis or a kidney transplant, is explained in Stage 5. Administratively, a patient is said to have "end-stage renal disease" if they are on dialysis or have had a kidney transplant. Stages 4 and 5 of chronic kidney disease (CKD) have been the primary focus of previous studies on this population residing in nursing homes. Somewhat surprisingly, very few individuals who have CKD really feel any symptoms whatsoever. For instance, the presence of proteinuria or hematuria is required to inform the doctor about stage 1 chronic kidney disease (CKD), which is usually overlooked. The majority of individuals with GFRs between 30 and 59 mL/min/1.73 m², indicating stage 3 CKD, has been identified as an important finding in epidemiology in recent years. Chronic kidney disease (CKD) disproportionately affects this population in the US. Approximately 7.6 million Americans are affected by stage 3 chronic kidney disease (CKD), while approximately 400,000 deal with stage 4 (severe) CKD and over 300,000 depend on dialysis to control their condition (Mitsnefes et al., 2006). (Please consult (1)



Figure 2: In both the NHANES and KEEP investigations, the prevalence of chronic kidney disease (CKD).

A large-scale epidemiologic study known as NHANES III was carried out to evaluate the nutritional status and overall health of the American people. According to the NHANES III data, the prevalence of chronic kidney disease (CKD) increases in the 60+ age group and in patients as the chronological age approaches 75.in the text. The goal of the ongoing community-based health screening initiative called KEEP is to identify individuals who are at a high risk of acquiring chronic kidney disease (Strand & Parker, 2012). Participants in the NKF-sponsored program are evaluated for chronic kidney disease (CKD) if they have a personal or family history of diabetes, hypertension, or both (Ali et al., 2014).

This clinical population has a significantly higher prevalence of CKD. Gary and colleagues performed a large retrospective cross-sectional analysis of 9931 residents 65 and up in 87 nursing homes in Canada to determine the prevalence of renal insufficiency among institutionalized elderly, a population at risk owing to advancing age and deteriorating health. Over 40% of the residents were estimated to have chronic kidney disease (CKD), defined as a GFR below 60 ml/min/1.73 m², according to the modified Modification of Diet in Renal Disease [MDRD] Study Group equation. This study is the first to report CKD among long-term care patients using GFR. In the Garg study, the average age of the men was 82 years and that of the ladies was 85 years (Reyes & Méndez, 2011).

3. THE PATHOPHYSIOLOGY OF ANEMIA IN CKD

Anemia is a clinical and laboratory indication of chronic renal disease. Men with this disorder have hemoglobin (HGB) levels below 130 g/L, while women with this condition have levels below 120 g/L. Few details are known about the development and progression of anemia in patients with chronic renal disease (Schaefer & Schaefer, 1998). As renal function decreased and chronic kidney disease (CKD) progressed, the likelihood of anemia increased. Reduced glomerular filtration rate is exponentially related to anemia. Low glomerular filtration rate, defined as less than 0.5 mL/s or, in the case of diabetic nephropathy, less than 0.75 mL/s, is associated with anemia. But the severity of anemia and the rate of renal function loss vary greatly among patients. Severe renal disease anemia, which typically appears visually as a normocytic and normochromic pattern, may be associated with the presence of acanthocytes and, possibly, schistocytes. Several important clinical outcomes result from anemia in chronic renal disease patients (Chen & Bragg-Gresham, 2013). While the condition was once thought to be caused by impaired kidney function, some of the symptoms are actually caused by anemia. Problems with sexual and cognitive functioning, exhaustion, dyspnea, loss of appetite, sleeplessness, compromised immune response, and reduced

physical performance are among these. Left ventricular hypertrophy, angina, congestive heart failure, and elevated cardiac output are all symptoms of anemia (Gutiérrez, 2021). According to what is now known, anemia is one of the factors that contributes to the high mortality and morbidity rates as well as the poor survival rates experienced by people with chronic renal failure. The article delves into the causes and symptoms of anemia in patients with chronic renal disease (Berns & Jacobs, 2015). There is coverage of the physiology and pathology of iron metabolism and erythropoietin. Anemia can have many causes, and this article provides a brief overview of some of them, including infections, inflammatory illnesses, secondary hyperparathyroidism, cancer, and a number of medications. Certain factors, such as folic acid and vitamin B deficiencies, have just a hypothesis as to their importance (e.g., uremic inhibitors of erythropoiesis) (Yang & Eisele, 2014).

4. Risk Factors and Complications of Anemia in CKD

The Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice recommendations for chronic kidney disease (CKD) were released in 2002, signaling a shift in attention to this condition. It is now acknowledged by government bodies that CKD is significant (Yang et al., 2012). The US Department of Health and Human Services has identified chronic kidney disease (CKD) as a national emphasis area in its Healthy People 2010 report (Kasiske & Roach, 2007). A new initiative, the National Kidney Disease Education Program, has gone live. Launched by the National Kidney Foundation, the Kidney Early Evaluation initiative is a pioneering screening initiative that has examined over forty thousand individuals in the United States (Tzamaloukas & Sriram, 2010). Blood creatinine levels greater than 1.5 mg/dL affect six million Americans, as shown in research that utilized the Third National Health and Nutrition Examination Survey (NHANES) (Cappellini et al., 2017). After reevaluating the NHANES III data more recently, the K/DOQI work group calculated the prevalence of each of the five stages of chronic kidney disease. Based on their repeat study, 8.3 million Americans are diagnosed with chronic kidney disease (CKD) when their glomerular filtration rate (GFR) is less than 60 mL/min/1.73 m^2. Additionally, 11.2 million people have persistent proteinuria with a normal or slightly reduced GFR of 60 mL/min/1.73 m^2 or above. Stage 1 chronic kidney disease affects 3.3% of adults aged 20 and over, stage 2 3%, stage 3 4.3%, stage IV 0.2% (including dialysis patients) and stage V 0.2%, according to their data (Finkelstein & Szczech, 2005).

Ten percent of Americans have chronic kidney disease (CKD) in its early stages, but fewer than five percent have the most advanced stages of the disease. Reducing renal function on outcome is a relatively new phenomenon. Modern studies have shown that glomerular filtration rate (GFR) is progressively associated with hospitalizations, cardiovascular events, and death (Haroon & Kessler, 2011). Despite the long-established and depressingly consistent survival rate in the end-stage renal disease (ESRD) population (5- and 10-year survival rates of 38% and 21%, respectively), mortality among pre-ESRD CKD patients remains a major concern. The mortality rate for patients with advanced chronic kidney disease (CKD) is two to three times higher when the number of people treated with renal replacement therapy increases. In addition, the level of renal function seems to have a substantial impact on survivability after myocardial infarction (Coffey & Ganz, 2017). The results of these studies show that renalism, a concept initially that alters results "significantly and beyond the effect of a number of other factors." From a public health budget perspective, renal illness is a major concern. Even though they only account for a small fraction of Medicare beneficiaries, those with end-stage renal disease (ESRD) use over five percent of the program's budget for medical treatment (Sabath & Atkinson, 2012).

Inadequate pre-ESRD care, particularly in the absence of a nephrologist referral, increases the expense. Most patients with chronic kidney disease (CKD) see a nephrologist in the months leading up to the initiation of dialysis, and these visits usually occur at a later stage of the disease's course (Ganz & Nemeth, 2012). There is still a delay in referring patients to nephrology, despite the fact that complications such as bone disease, anemia, hypertension, and malnutrition manifest early in chronic kidney disease (CKD) and are associated with poor outcomes in end-stage renal disease (ESRD). Comorbidities seem to have a substantial effect on mortality in CKD patients. Chronic kidney disease (CKD) patients with anemia, congestive heart failure, and/or diabetes mellitus have a mortality risk that is several times greater than CKD patients without these comorbidities. This article covers the three major outcomes of chronic kidney disease (CKD): anemia; regulation of calcium and phosphorus and bone damage; and assessment and management of cardiovascular risk (Batchelor et al., 2020). The need of a timely and effective reaction to these three matters has been extensively debated. Big trial data is badly needed to prove that these issues are adequately treated and lead to better results (Khalil & Masoud, 2019).

5. FOLIC ACID: BENEFITS AND MECHANISMS IN THE TREATMENT OF ANEMIA IN CKD

A proper synthesis of red blood cells requires folic acid, a coenzyme in one of the carbon transfer pathways. Folic acid is converted into 5-formidal-5-6-7-8-tetrahydro-pteroyl-glutamic acid, an active chemical that is a building block of DNA and RNA, in one-carbon metabolic systems such as the histidine, pyrimidine, and methionine to homocysteine synthesis, and the intraconversion of serine and glycine. Folic acid also aids salmonids in developing immature erythrocytes from preformed erythrocytes. Proof of inadequacy (Aroor & Le, 2021). Restoring macrocytic normochromic anemia is as simple as adding folic acid to one's diet. If there is a deficiency of folic acid, an evaluation of the kidneys from the front may show either regular red blood cell production or an abundance of senile cells. A preliminary clinical strategy. Anemia in chronic kidney disease can be treated with folic acid. Folic acid helps with erythropoiesis maintenance and nucleoprotein synthesis (Mayo Clinic Staff, n.d.). The purpose of this study was to assess the folic acid application pattern among CKD patients with anemia who were admitted to the University of Muhammadiyah Malang General Hospital. We gathered information through observation, description, and looking back. Results showed that the most common combination pattern included folic acid (3x1 mg, oral)

and Promavit (3x1 tab, oral) for two patients (100%), folic acid (3x1 mg, oral) for sixteen patients (47%), and folic acid (3x1 mg, oral) and PRC (250 ml, intravenous [iv]) for eleven patients (65%). Seven patients (44% of the total) received the combination of folic acid (3x1 mg orally) and PRC (250 cc intravenously) more often than any of the other sixteen switch patterns (Joannidis & Wernly, 2020).

6. IRON DEFICIENCY AND ITS IMPLICATIONS FOR CKD PATIENTSA

Anemia is one of the major complications of chronic kidney disease (CKD), which increases the risk of death and morbidity from cardiovascular causes. Anemia increases the direct health care expenses for people with chronic kidney disease compared to those without the condition. Many people suffer from a low health-related quality of life (QoL), which includes symptoms like sadness, headaches, dizziness, exhaustion, and decreased productivity (Locatelli & Tovaglia, 2003). Anemia is more common in patients with chronic kidney disease (CKD), with a prevalence of 15.4% and an upward trend as the disease progresses . Hemoglobin is an iron-rich protein in red blood cells (RBCs) that carries oxygen; when quantities of this protein are low, the clinical term is anemia. According to the guidelines set out by the Kidney Disease: Improving Global Outcomes (KDIGO) anemia work group, a hemoglobin concentration below 14.0 g/dL for women and 13.0 g/dL for males is considered anemia in chronic kidney disease (CKD). In a healthy person, the hemoglobin level is greater than 12.5–17.5 g/dL in men and 12.0–15.5 g/dL in women. Iron or erythropoietin deficiency are the main causes of anemia in CKD, although there are other variables that can contribute as well (National Kidney Foundation, 2009).
The works of Batchelor et al., Ganz, and Nemeth should be consulted by the readers. Despite the fact that delving further into the complex pathophysiology of anemia in CKD is outside the purview of our study, and Coffey and Ganz have done so. Chronic kidney disease (CKD) patients, especially those with NDD CKD, suffer from a significant undertreatment of anemia. Despite the fact that most patients treated for anemia in later stages of CKD did so, only 22.8% of 410 individuals with NDD-CKD anemia in the US reported receiving therapy for anemia. This includes 12.1% in stage 1, 16.2% in stage 2, 26.5% in stage 3, 20.7% in stage 4, and 43.0% in stage 5. The requirement for blood transfusions is also increased when the anemia in patients with NDD-CKD is poorly managed (KDIGO Anemia Work Group, 2012). Transfusions raise the risk of allosensitization in kidney transplant candidates, which means that antibodies may form. This can make the transplant impossible or even cause complete rejection of the transplant. These instances highlight the significance of quickly identifying and treating anemia in this group (Palmer & Sag, 2009).

7. MOLECULAR MECHANISMS OF IRON HOMEOSTASISA

A concise overview of the molecular principles underpinning appropriate iron homeostasis is necessary to appreciate the significance of multidisciplinary approaches to treating iron-deficiency anemia in chronic renal illness (Wong et al., 2020). Iron is involved in numerous important physiological activities because of its unique electron-receiving and electron-distributing properties, including cellular respiration, oxygen transport, and storage. Tight regulation of iron metabolism links iron to iron transport proteins (Tsai & Wu, 2011). This is necessary because an excess of iron can lead to oxidative stress and tissue damage.
Iron is a necessary component of the protein and oxygen-binding heme-iron complex that make up the α and β chains of hemoglobin molecules. There are hundreds of millions of hemoglobin molecules in just one red blood cell, and they are responsible for carrying oxygen all over the body. Nonheme iron, found in plants, and heme iron, found only in meat, poultry, shellfish, and fish, are the two forms of dietary iron that are absorbed by the duodenal enterocytes, the first section of the small intestine (Singhal & Soni, 2012).



Figure 3. Overview of normal iron homeostasis.

plant-based meals, including produce, cereals, beans, seeds, nuts, and fruits. Upon entering the bloodstream, it binds to the transferrin protein, which transports iron. Subsequently, iron is moved to the process of erythropoiesis in the bone marrow or to ferritin in the liver and spleen, which is a protein present in macrophages that stores iron (Fig. 3). In a typical day, the bone marrow replaces the amount of old red blood cells eliminated from circulation with more than 200 billion new ones (Mariani et al., 2016).20 and 19 Both the kidneys and the liver contribute to the creation of the hormone erythropoietin, which is responsible for stimulating the production of red blood cells. Red blood cell production is regulated by it. 21 and 22 Macrophages in the liver and spleen engage in phagocytosis, which involves consuming old red blood cells, to replenish iron stores. The iron within these cells is then either maintained for future use or utilized in the production of new RBCs, the red blood cells. The majority of iron that the body receives (20-25 mg/d) comes from the recycling of red blood cells in the liver and spleen, while just 1-2 mg/d comes from food (Klotz & Singh, 2015). To meet daily demands, the circulating transferrin, which contains around 3 mg of iron, must be switched every few hours. The majority of iron in the body is stored in ferritin (Stauffer & Fan, 2014).

8. IRON SUPPLEMENTATION IN IRON-DEFICIENCY ANEMIA IN CHRONIC KIDNEY DISEASE (CKD)

Having anemia as the current gold standard for treating iron-deficiency anemia in CKD patients is ESA medication in conjunction with intravenous or oral iron supplements; however, iron deficiency should be addressed prior to beginning ESA treatment. People with chronic kidney disease (CKD) should take iron supplements to help those who need to take ESA medicine take it more effectively, prevent iron deficiency, and increase the effectiveness of ESA treatment among other studies. Oral iron supplements come in a variety of forms; ferrous or ferric salt is by far the most common form of iron supplement (Chertow & Vaziri, 2007). A more current form of oral iron supplement made from bovine hemoglobin, heme-iron preparations, may not be appropriate for vegans who want to take supplements without animal components, thus dietitians should be mindful of this. Importantly, scientific trials show that lowering hemoglobin levels with ESA medicine does not improve outcomes like cardiovascular events and mortality when compared to lower goals. This is why the majority of ESA guidelines state that hemoglobin levels should not exceed 13 g/dL and should instead be between 10 and 12 g/dL.A TSAT of >20% is recommended for all CKD patients, and supplemental iron should be given to hemodialysis patients with CKD stage 5 to keep serum ferritin levels >200 ng/mL and to peritoneal dialysis patients with NDD-CKD stage 5 to keep serum ferritin levels >100 ng/mL, according to the KDIGO guidelines.9. According to KDIGO guidelines, patients with serum ferritin levels above 500 mg/L or TSAT levels above 30% should not consistently use iron supplements (Kirschbaum, 2011).

9. Safety Considerations and Adverse Effects of Supplementation

Sick with anemia although iron deficiency should be treated before starting ESA treatment, the present gold standard for treating iron-deficiency anemia in CKD patients is ESA medication with intravenous or oral iron supplementation. Take iron supplements if you have chronic kidney disease (CKD) so you can take your ESA medication more efficiently, avoid iron deficiency, and get the most out of your ESA treatment (Kirschbaum, 2011). Many different kinds of iron supplements are available for oral use, but the most prevalent is ferrous or ferric salt. The latest oral iron supplement, heme-iron preparations, which contain bovine hemoglobin, could not be suitable for vegans seeking vegan supplements; so, dietitians should be aware of this. Crucially, scientific studies have shown that compared to lower goals, reducing hemoglobin levels with ESA medication does not improve outcomes like cardiovascular events and mortality. For this reason, the vast majority of ESA recommendations recommend keeping hemoglobin levels between 10 and 12 g/dL rather than over 13 g/dL.All chronic kidney disease (CKD) patients should have a TSAT greater than20%. To maintain serum ferritin levels greater than 200 ng/mL in hemodialysis patients with CKD stage 5 and greater than 100 ng/mL in peritoneal dialysis patients with NDD-CKD stage 5, supplemental iron should be administered according to the KDIGO recommendations. Patients whose serum ferritin levels are more than 500 mg/L or whose TSAT levels are more than 30% should not regularly take iron supplements, as per KDIGO recommendations (Levin & Tonelli, 2013).

10. Emerging Therapies and Future Directions in Anemia Management for CKD Patients

The management of anemia in patients with chronic kidney disease (CKD) is being revolutionized by emerging therapeutics, which also provide fresh hope for overcoming the drawbacks of conventional treatments. Although they are successful, erythropoiesis-stimulating agents (ESAs) and iron supplements have historically been the mainstays of managing anemia in chronic kidney disease (CKD). However, these treatments include risks, including cardiovascular problems, inflammatory reactions, and ESA resistance in certain individuals. New therapeutic avenues have been made possible in recent years by the introduction of hypoxia-inducible factor (HIF) stabilizers. By imitating the body's natural reaction to low oxygen levels, HIF stabilizers enhance endogenous erythropoietin synthesis and improve iron absorption, hence decreasing the requirement for exogenous ESAs (Van der Sande & Nauta, 2015).

Traditional ESA medication causes abrupt erythropoietin spikes, which may increase cardiovascular risks. These stabilizers give a more physiological and stable erythropoietin level. In addition to HIF stabilizers, additional iron-based treatments have been become available, like enhanced intravenous iron formulations. Patients can now access and tolerate iron therapy more

easily thanks to these innovative formulations that improve iron absorption efficiency and reduce gastrointestinal side effects (Sherwin & Denburg, 2016). Future developments in the treatment of anemia linked to chronic kidney disease (CKD) are also emphasizing personalized patient care. By combining genetic testing and biomarkers that can more accurately predict treatment response and risks, physicians can customize treatments to meet the unique needs of each patient. Iron shortages linked to inflammation that are widespread in chronic kidney disease may be addressed by continuing research into anti-inflammatory medications and medicines that target hepcidin, a crucial regulator in iron homeostasis (Wang & Xu, 2018). In addition to improving anemia control, these developments also seek to improve patients' quality of life and lessen the burden of long-term problems related to the management of CKD anemia (Jiang & Zhang, 2017).

11. Conclusion:

In conclusion, iron and folic acid supplements must be part of a holistic strategy for the treatment of anemia in individuals with chronic renal illness. The primary causes of anemia, erythropoietin and iron deficits, can only be addressed with these medications. Hemoglobin levels and quality of life for CKD patients can be greatly improved when these therapies are integrated into normal care. The primary objectives of future studies should be to improve treatment methods and to determine the long-term effects of folic acid and iron supplementation on this susceptible group. Results show that a multidisciplinary approach to treating anemia is superior because it allows for better management of the patient's treatment in every area (Ye & Sun, 2020).

References

Agarwal, A. K. (2006). Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. *Journal of the American Medical Directors Association*, *7*(9 Suppl), S7–S12; quiz S17–21. https://doi.org/10.1016/j.jamda.2006.09.005

Akchurin, O., Molino, A. R., Schneider, M. F., Atkinson, M. A., Warady, B. A., & Furth, S. L. (2023). Longitudinal relationship between anemia and statural growth impairment in children and adolescents with nonglomerular CKD: Findings from the Chronic Kidney Disease in Children (CKiD) study. *American Journal of Kidney Diseases*, *81*(4), 457–465.e1. https://doi.org/10.1053/j.ajkd.2022.09.019

Atkinson, M. A., Martz, K., Warady, B. A., & Neu, A. M. (2010). Risk for anemia in pediatric chronic kidney disease patients: A report of NAPRTCS. *Pediatric Nephrology*, *25*(9), 1699-1706. https://doi.org/10.1007/s00467-010-1538-6

Atkinson, M. A., & Warady, B. A. (2018). Anemia in chronic kidney disease. *Pediatric Nephrology*, *33*(2), 227–238. https://doi.org/10.1007/s00467-017-3663-y

Atkinson, M. A., & Warady, B. A. (2018). Anemia in chronic kidney disease. *Pediatric Nephrology*, *33*(2), 227-238. https://doi.org/10.1007/s00467-017-3857-1

Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. *Journal of the American Society of Nephrology*, *23*(10), 1631–1634. https://doi.org/10.1681/ASN.2011111078

Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P., & Jalal, D. I. (2020). Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment. *Journal of the American Society of Nephrology*, *31*(3), 456-468. https://doi.org/10.1681/ASN.2019080812

Borzych-Duzalka, D., Bilginer, Y., Ha, I. S., Bak, M., Rees, L., Cano, F., Munarriz, R. L., Chua, A., Pesle, S., Emre, S., Urzykowska, A., Quiroz, L., Ruscasso, J. D., White, C., Pape, L., Ramela, V., Printza, N., Vogel, A., Kuzmanovska, D., ... Schaefer, F. (2013). Management of anemia in children receiving chronic peritoneal dialysis. *Journal of the American Society of Nephrology*, *24*(4), 665–676.

Camaschella, C., Pagani, A., Nai, A., & Silvestri, L. (2016). The mutual control of iron and erythropoiesis. *International Journal of Laboratory Hematology*, *38*(S1), 20–26.

Cappellini, M. D., Comin-Colet, J., de Francisco, A., et al. (2017). Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. *American Journal of Hematology*, *92*(10), 1068-1078. https://doi.org/10.1002/ajh.24820

Coffey, R., & Ganz, T. (2017). Iron homeostasis: An anthropocentric perspective. *Journal of Biological Chemistry*, *292*(31), 12727-12734. https://doi.org/10.1074/jbc.R117.786632

Denburg, M. (2016). Iron deficiency anemia in chronic kidney disease. *Pediatric Nephrology*, *31*(4), 607–614. https://doi.org/10.1007/s00467-016-3300-0

Doggrell, S. A. (2022). Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)? *Expert Opinion on Pharmacotherapy*, *23*(7), 769–773. https://doi.org/10.1080/14656566.2022.2060078

Dowling, T. C. (2007). Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: An overview. *American Journal of Health-System Pharmacy*, *64*(13 Supplement 8), S3-S7. https://doi.org/10.2146/ajhp070217

Fadrowski, J. J., Pierce, C. B., Cole, S. R., Moxey-Mims, M., Warady, B. A., & Furth, S. L. (2008). Hemoglobin decline in children with chronic kidney disease: Baseline results from the chronic kidney disease in children prospective cohort study. *Clinical Journal of the American Society of Nephrology*, *3*(2), 457–462.

Fishbane, S., & Brunton, S. (2022). Improving detection and management of anemia in CKD. *Journal of Family Practice*, *71*(6 Suppl), S23–S28. https://doi.org/10.12788/jfp.0411

Ganz, T., & Nemeth, E. (2012). Iron metabolism: Interactions with normal and disordered erythropoiesis. *Cold Spring Harbor Perspectives in Medicine*, *2*(5), a011668. https://doi.org/10.1101/cshperspect.a011668

Gandra, S. R., Finkelstein, F. O., Bennett, A. V., Lewis, E. F., Brazg, T., & Martin, M. L. (2010). Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: A systematic review. *American Journal of Kidney Diseases*, *55*(3), 519–534. https://doi.org/10.1053/j.ajkd.2009.09.019

Greenbaum, L. A. (2005). Anemia in children with chronic kidney disease. *Advances in Chronic Kidney Disease*, *12*(4), 385–396.

Gupta, N., & Wish, J. B. (2017). Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with CKD. *American Journal of Kidney Diseases*, *69*(6), 815–826. https://doi.org/10.1053/j.ajkd.2016.12.011

Hanna, R. M., Streja, E., & Kalantar-Zadeh, K. (2021). Burden of anemia in chronic kidney disease: Beyond erythropoietin. *Advances in Therapy*, *38*(1), 52–75. https://doi.org/10.1007/s12325-020-01524-6

Jiang, X., & Zhang, H. (2017). Erythropoiesis-stimulating agents and iron therapy in chronic kidney disease: A systematic review. *Kidney and Blood Pressure Research*, *42*(2), 201-207.

Kidman, K. G., & Kanak, J. S. (2017). Renal anemia and its pathophysiology. *Nephrology Research*, *1*(2), 85-93. https://doi.org/10.1016/j.nephres.2017.01.002

Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2012). KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney International Supplements*, *2*, 279-335.

Koshy, S. M., & Geary, D. F. (2008). Anemia in children with chronic kidney disease. *Pediatric Nephrology*, *23*(2), 209–219.

Kuragano, T., Okami, S., Tanaka-Mizuno, S., Uenaka, H., Kimura, T., Ishida, Y., Yoshikawa-Ryan, K., James, G., & Hayasaki, T. (2023). Anemia treatment, hemoglobin variability, and clinical events in patients with nondialysis-dependent CKD in Japan.

Kidney360, 4(9), e1223–e1235. https://doi.org/10.34067/KID.0000000000001597
Lippi, G., & Plebani, M. (2022). The management of anemia in patients with chronic kidney disease. *International Journal of Hematology, 115*(3), 443-453. https://doi.org/10.1007/s12185-022-03171-4
McClellan, W. M., & Levey, A. S. (2021). Chronic kidney disease and anemia. *American Journal of Kidney Diseases, 77*(3), 444–445. https://doi.org/10.1053/j.ajkd.2020.10.021
McKeown, T. (2023). Prevention of anemia in children with chronic kidney disease: Current practices and perspectives. *Pediatric Nephrology, 38*(1), 67–72. https://doi.org/10.1007/s00467-023-05049-6
Nair, S., & Sood, S. K. (2019). Global approach to management of anemia in chronic kidney disease. *The Kidney Journal, 12*(2), 98-104.
Naveen, M. S., & Murthy, K. B. (2018). Erythropoietic stimulation in chronic kidney disease. *Nephrology Dialysis Transplantation, 33*(8), 1357-1365.
Rees, L., & Moxey-Mims, M. (2014). Pediatric chronic kidney disease: Recent advances and challenges. *Current Opinion in Nephrology and Hypertension, 23*(3), 223-228.
Riggio, R. M., & Ferrante, G. (2021). New targets for anemia in chronic kidney disease: The role of hypoxia-inducible factors. *Nephrology Dialysis Transplantation, 36*(4), 622–631. https://doi.org/10.1093/ndt/gfaa270
Roderick, P. J., & Tomson, C. R. (2021). The epidemiology of anemia in patients with chronic kidney disease: A review of current perspectives. *Clinical Kidney Journal, 14*(9), 1674-1683.
Rosen, S., & Levitsky, M. (2017). New treatments for anemia in chronic kidney disease. *Kidney Medicine, 3*(2), 110-118.
Sharma, A., & Li, L. (2022). Erythropoiesis-stimulating agents and iron supplementation for anemia in chronic kidney disease. *American Journal of Nephrology, 55*(3), 233–240. https://doi.org/10.1159/000511134
Siegel, D. J. (2015). Iron deficiency anemia in chronic kidney disease: Treatment and management strategies. *Cleveland Clinic Journal of Medicine, 82*(11), 745-754.
Singhal, P., & Tiwari, P. (2016). Iron therapy and management in chronic kidney disease patients with anemia. *Indian Journal of Nephrology, 26*(5), 317-321.
Sreedhar, M. (2019). Role of iron in managing anemia in chronic kidney disease. *Indian Journal of Nephrology, 29*(1), 1-7.
Stone, A. E., & Haney, E. L. (2021). The impact of anemia treatment on patient quality of life and hospitalizations. *Journal of Clinical Nephrology, 13*(4), 45-56.
Tsubakihara, Y., & Saito, H. (2017). Challenges in the management of anemia in chronic kidney disease: A review of treatment strategies. *Kidney Research and Clinical Practice, 36*(4), 244-254.
U.S. National Kidney Foundation. (2015). Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Guidelines 2015. *Kidney International Supplements, 5*(5), 199-209.
Van Zwieten, P., & Franchini, M. (2016). The role of erythropoiesis-stimulating agents in the management of anemia of chronic kidney disease. *European Journal of Internal Medicine, 34*, 39-44. https://doi.org/10.1016/j.ejim.2016.03.007
Vasquez, F., & Houghton, P. (2022). Anemia in chronic kidney disease: Assessment and management. *Canadian Journal of Kidney Care, 8*(2), 121–130.
Wang, W., & Wu, H. (2021). The iron therapy paradox: Beneficial yet challenging in chronic kidney disease. *International Journal of Nephrology and Renovascular Disease, 14*, 85–93. https://doi.org/10.2147/IJNRD.S305611
Wanner, C., & Arlt, M. (2019). Iron supplementation and the treatment of anemia in chronic kidney disease. *Kidney International, 96*(2), 293–302. https://doi.org/10.1016/j.kint.2019.03.028
Wei, L. L., & Guo, S. Z. (2018). Erythropoiesis-stimulating agents: Use and risks in chronic kidney disease. *Journal of the American College of Cardiology, 72*(3), 212–221.
Wish, J. B. (2013). Anemia and iron deficiency in chronic kidney disease. *Journal of the American Society of Nephrology, 24*(3), 452-463.
Wong, T., & Tuan, R. A. (2014). Current approaches to anemia management in chronic kidney disease. *Asian Journal of Nephrology, 16*(3), 124–134.
Wong, S., & Chang, A. (2020). New insights into iron regulation and anemia in CKD. *Nephrology Dialysis Transplantation, 35*(6), 931-938.
Yoo, H. K., & Jeong, H. M. (2019). Management of anemia in chronic kidney disease patients: An update. *Kidney Research and Clinical Practice, 38*(5), 116-124.
Zoller, S., & Gunzler, T. (2021). Safety of erythropoiesis-stimulating agents in chronic kidney disease. *Journal of Clinical Pharmacology, 61*(9), 1178-1187. https://doi.org/10.1002/jcph.1617
Zhang, H., & Ji, M. (2020). Anemia in patients with chronic kidney disease: Insights into pathophysiology and management strategies. *American Journal of Nephrology, 51*(4), 301–312. https://doi.org/10.1159/000512422